The monthly cost of a private prescription for Mounjaro is set to exceed £300 from next month – worrying news for the half a ...

What started as a medical solution to diabetes has exploded into a worldwide weight-loss trend, with demand skyrocketing as ...

A NEW drug developed to combat diabetes and obesity melts fat at double the rate of other GLP-1 drugs, scientists say. The ...

BRITAIN has gone fat jab crazy — with sales of Wegovy soaring by more than 2,000 per cent in the past month. Dieters are ...

Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

Dr Shazia Malik - a consultant obstetrician and gynaecologist for The Portland Hospital - discussed the pros and cons of ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

GLP-1 receptor agonists such as the popular weight loss/diabetes therapies Mounjaro, developed by Eli Lilly (NYSE:LLY), and ...

The Irish arm of SSP (Select Service Partner), the London-based group that runs Burger ...

Novo Nordisk, the maker of the blockbuster diabetes drug Ozempic, is at the center of a brewing legal storm. Once celebrated ...